Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.

Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020

Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead's SYK Inhibitor Portfolio

Bausch Health Companies Inc

Johnson & Johnson

Pfizer

Author Gerald Posner discusses his latest book, a history of the pharmaceutical industry.

Capital Interviews: Gerald Posner Discusses His New Book On Pharma, The Pandemic, And The Future Of The Industry

Bloomin' Brands

BioNTech SE

Denny's

Brinker International

Moderna

Ruth's Hospitality Group

Chains such as Outback Steakhouse, Chili's, Denny's, and Ruth's Chris were climbing on a positive vaccine trial.

Why Casual Dining Restaurant Stocks Were Gaining Today

Eli Lilly

After a few years hanging out quietly on the sidelines, the Health Care sector roared back to prominence this year as COVID-19 ravaged the globe. Suddenly, vaccines and antibodies catapulted into the headlines, drawing attention to biotech and pharma amid a race to treat or prevent the virus.

GILDing” The Lilly: Vaccines, Treatments For Virus In Spotlight Ahead Of Health Care Q2 Earnings

Gilead Sciences' remdesivir has the potential to save many lives -- and enrich many investors of the company's stock in the process.

Why Gilead Sciences Is the Front-Runner in the COVID-19 Treatment Race

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

A new formulation of remdesivir could open up a multibillion-dollar market.

Here's Gilead Sciences' Great COVID-19 Opportunity That You'll Really Want to Watch

BioCryst Pharmaceuticals

Biosig Technologies Inc

CytoDyn Inc.

Eiger BioPharmaceuticals

Immunic Inc

Regeneron Pharmaceuticals

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

Gilead released new data and claims it shows mortality risk decreases by 62% in patients given Remdesivir.

Gilead: Remdesivir Reduces Mortality Risk

Gilead (GILD) announces a comparative analysis of remdesivir, wherein the drug was associated with a 62% reduction in risk of mortality compared to standard of care.

Gilead Presents Additional Data on Coronavirus Drug Remdesivir

There’s still time, but investors should act soon.

After Remdesivir Trials, Is It Too Late to Buy Gilead Stock?

A retrospective analysis said the still-experimental antiviral infusion significantly reduces COVID-19 patients' risk of death.

Why Gilead Sciences' Successful COVID-19 Results Fell Flat

Stock Market Today: Gilead Gives Stocks a Booster Shot

Gilead's Remdesivir Cuts Risk of COVID-19 Death by 62% -- Maybe

U.S. stocks rose on Friday as a positive update from Gilead Sciences Inc's antiviral drug to treat COVID-19 countered nerves over a record rise in coronavirus cases in the United States that threatens to further impact companies.

Wall Street gains as Gilead data offsets virus fears; Dow leads gains

The market opened flat as investors weigh a recent spike in new cases with positive vaccine news.

Dow Jumps 200 Points After Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

Ford Motor Company

NEW YORK (LPC) - Bank lenders for high-quality US companies are taking different refinancing avenues as they seek to extend maturities on billions of US dollars in loans at a time when the Covid-19 pandemic has made liquidity a top priority.

U.S. companies seeking capital during pandemic test bank market's new normal

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: Gilead Sciences

Netflix

Major market benchmarks moved in different directions Friday morning.

Stock Markets Open Mixed Friday as Netflix Gets Upgraded, Gilead Reports Positive Coronavirus Treatment Results

Gilead Sciences, Inc. (NASDAQ: GILD) shares are seeing some upward momentum following the biopharma's announcement of additional data on its COVID-19 treatment candidate remdesivir.

Gilead's Remdesivir Data Shows Improved Clinical Recovery, Reduced Death Rate

Stocks ticked higher after Gilead’s coronavirus treatment showed positive data.

Stocks Cut Losses After Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

Gilead Sciences said Friday its experimental coronavirus treatment, remdesivir, lowered the risk of death by 62% in a Phase 3 study — prodding GILD stock higher.
The post Gilead Says Coronavirus Drug Lowers Risk Of Death; Shares Pop appeared first on Investor's Business Daily.

Gilead Says Coronavirus Drug Lowers Risk Of Death; Shares Pop

U.S. stock-index futures turned positive on Friday after a report from Gilead Sciences indicated that its experimental treatment for coronavirus was seeing positive results in reducing deaths.

Dow and broader stock-market futures turn positive amid upbeat report on Gilead's experimental coronavirus treatment

Shares of Gilead Sciences Inc. GILD, -1.19% gained 2.0% in premarket trading on Friday after the drugmaker disclosed findings from a new analysis of previously disclosed clinical trial data that found the experimental therapy remdesivir can reduce the risk of mortality in COVID-19 patients by 62%, when compared to the standard of care.

News for Gilead Sciences Stock (GILD)